TABLE 2.

Summary of recommendations from international societies on the prevention of thromboembolic events in pregnant patients with COVID‐19

Society (country)	Antepartum, self‐isolating at home	Antepartum, hospitalized	Postpartum
Royal College of Obstetricians and Gynaecologists (RCOG) (UK) 43	Ensure hydration and mobilization. Those already receiving thromboprophylaxis should continue. If VTE risk score at booking visit is ≥3, prophylactic LMWH should be recommended (and continued until recovery from illness – 7‐14 days).. For others, assess VTE risk through a remote or in‐person clinical review and prescribe thromboprophylaxis on a case‐by‐case basis.	VTE prophylaxis should be prescribed during admission unless contraindicated or birth expected within 12 hours.	Conduct VTE risk‐assessment following birth. For those with confirmed SARS‐CoV‐2 infection, prescribe prophylactic LMWH, unless contraindicated ×10 days.
Queensland Clinical Guidelines (Australia) 52	Consider VTE prophylaxis even in the absence of other risk factors. Reduced mobility resulting from self‐isolation at home or from admission may also increase risk.
Institute of Obstetricians and Gynaecologists ‐ Royal College of Physicians of Ireland (RCPI) (Ireland) 53	Isolation at home is likely to cause a significant reduction in daily mobility, which may increase the risk of VTE in all pregnant women. The risk of thrombosis among this group is high and consideration for VTE prophylaxis should occur following discussion with a hematologist.	VTE risk assessment should be carried out on all admitted with COVID‐19 infection. VTE prophylaxis with LMWH at standard obstetric dosing is recommended unless within 12 hours of birth.	For those not critically ill, prophylaxis should be considered for at least 10 days postpartum as per guidelines on sepsis in the peripartum period. For those critically ill, prophylaxis should be continued following discharge from ICU for 6 weeks.
Philippine Obstetrical and Gynecological Society (POGS); Philippine Society Of Maternal Fetal Medicine (PSMFM) (Philippines) 54	Administer Prophylactic LMWH, unless delivery is expected within the next 12 hours.		NA
The International Society of Ultrasound in Obstetrics & Gynecology (ISUOG) (International) 55	Prophylactic LMWH should be considered in outpatient self‐isolating patients on a case‐by‐case basis, according to risk factors.	Thromboprophylaxis must be considered for all pregnant women managed as inpatients, especially those with severe disease, unless delivery is imminent	NA
International Society for Infectious Diseases in Obstetrics and Gynecology (ISIDOG) 56	Every parturient diagnosed with COVID‐19 should receive LMWH for at least 10 days, even in the absence of other risk factors. It should even be considered to increase the dose of the LMWH in severely ill patients.		LMWH for thromboprophylaxis recommended. Dose should preferably double if severe COVID‐19 illness.
Collège National Des Gynécologues et Obstétriciens Français (CNGOF) (France) 57	Risk stratification according to personal risk factors, and oxygen requirements: Weak risk = no prophylaxis, Medium risk = LMWH given at standard prophylaxis, High risk = LMWH given at higher prophylaxis dosage. Duration of prophylaxis should be maintained until recovery. Do not start prophylaxis if delivery is approaching		NA
Swiss Society of Gynecology and Obstetrics (Switzerland) 58	COVID‐19 patients have a higher thromboembolic risk, which is further increased by the pregnancy and postpartum situation. Consequently, thromboembolic prophylaxis should be provided on an interdisciplinary basis for COVID‐19 patients during the pregnancy and postpartum.
Swedish Society of Obstetrics and Gynecology (Sweden) 59	Patients with mild to moderate symptoms = normal dose prophylaxis; Patients with pronounced symptom picture, where immobilizing hospital care is necessary; regardless of hemostasis effect = High‐dose prophylaxis, and correction of hemostasis if necessary. This assessment must be done individually. Doses are based on entry weight being above or below 90 kg.
COVID Collaborative Group, Barcelona (Spain) 60	In women with infection >4 weeks before delivery, thromboprophylaxis should follow standard criteria. Prolonged bed‐rest should be discouraged given the risk of thrombosis associated both with pregnancy and COVID infection.	Prophylactic LMWH is indicated during hospitalization and 2 weeks thereafter (independent of D‐dimer levels), after obtaining consent for compassionate use	Postpartum prophylactic LMWH is indicated during hospitalization and 6 weeks thereafter, due to risk of deep venous thrombosis and pulmonary thromboembolism in patients with severe COVID. Doses based on entry weight being above or below 80 kg

LMWH, low molecular weight heparin; VTE, venous thromboembolism.